Amgen Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amgen Inc. with three other
companies in this sector in UNITED STATES :
Biogen Inc
(2019
sales of $14.38 billion
of which 100%
was Biopharmaceutical),
Grifols SA
($5.70 billion
of which 78%
was Bioscience), and
Gilead Sciences, Inc.
($22.45 billion
of which 100%
was discovery, development and commercializa).
Sales Analysis.
Amgen Inc. reported sales of $23.36 billion
for the
year ending
December of 2019.
This
represents
a
decrease of 1.6%
versus 2018, when the company's sales were $23.75 billion.
Contributing to the drop in overall sales was the 68.9% decline
in Sensipar, from $1.77 billion to $551.00 million.
There were also decreases in sales in
Neulasta (down 28.0% to $3.22 billion)
and
Aranesp (down 7.9% to $1.73 billion)
and
Other Revenues (down 4.6% to $1.16 billion)
and
Epogen (down 14.2% to $867.00 million)
.
However, these declines were partially offset by the increase in sales of
Enbrel (up 4.2% to $5.23 billion)
and
Other Products (up 15.2% to $4.96 billion)
and
Prolia (up 16.6% to $2.67 billion)
and
Xgeva (up 8.3% to $1.94 billion)
.